Edition:
United Kingdom

Moleculin Biotech says working to resubmit IND application for annamycin


Tuesday, 23 May 2017 

May 23 (Reuters) - Moleculin Biotech Inc :Moleculin Biotech issues shareholder update on FDA designation of orphan drug and IND status for annamycin.Moleculin Biotech - working to resubmit IND application for annamycin and to announce co may begin Phase I/II clinical trials by end of July of 2017.Moleculin Biotech - if unable to obtain CMC data on timely basis,will delay resubmitting ind application for annamycin,which will delay clinical trials.